Clinical Trial Update: A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial investigating mosunetuzumab consolidation for older patients with diffuse large B-cell lymphoma who have detectable circulating…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Mosunetuzumab (mosunetuzumab)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Danielle Wallace | Conditions: Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Status: RECRUITING